Incyte Corporation (INCY)
USD 60.96
(-2.4%)
USD 60.96
(-2.4%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.78 Billion USD | 16.11% |
| 2022 | 5.84 Billion USD | 18.4% |
| 2021 | 4.93 Billion USD | 38.54% |
| 2020 | 3.56 Billion USD | 3.92% |
| 2019 | 3.42 Billion USD | 29.52% |
| 2018 | 2.64 Billion USD | 14.9% |
| 2017 | 2.3 Billion USD | 40.52% |
| 2016 | 1.63 Billion USD | 62.65% |
| 2015 | 1 Billion USD | 21.37% |
| 2014 | 830.06 Million USD | 31.85% |
| 2013 | 629.56 Million USD | 90.54% |
| 2012 | 330.41 Million USD | 0.44% |
| 2011 | 328.96 Million USD | -32.81% |
| 2010 | 489.58 Million USD | -31.28% |
| 2009 | 712.39 Million USD | 206.55% |
| 2008 | 232.38 Million USD | -15.71% |
| 2007 | 275.69 Million USD | -22.03% |
| 2006 | 353.6 Million USD | -5.48% |
| 2005 | 374.1 Million USD | -27.63% |
| 2004 | 516.91 Million USD | 36.19% |
| 2003 | 379.54 Million USD | -31.26% |
| 2002 | 552.13 Million USD | -21.74% |
| 2001 | 705.55 Million USD | -20.44% |
| 2000 | 886.82 Million USD | 299.65% |
| 1999 | 221.9 Million USD | -3.65% |
| 1998 | 230.3 Million USD | 19.26% |
| 1997 | 193.1 Million USD | 188.64% |
| 1996 | 66.9 Million USD | 15.74% |
| 1995 | 57.8 Million USD | 101.39% |
| 1994 | 28.7 Million USD | 63.07% |
| 1993 | 17.6 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 7.13 Billion USD | 5.21% |
| 2024 Q3 | 5.01 Billion USD | 7.52% |
| 2024 Q2 | 4.66 Billion USD | -34.67% |
| 2023 Q2 | 6.2 Billion USD | 7.08% |
| 2023 FY | 6.78 Billion USD | 16.11% |
| 2023 Q3 | 6.38 Billion USD | 2.9% |
| 2023 Q4 | 6.78 Billion USD | 6.17% |
| 2023 Q1 | 5.79 Billion USD | -0.74% |
| 2022 Q3 | 5.51 Billion USD | 3.59% |
| 2022 Q2 | 5.31 Billion USD | 5.24% |
| 2022 FY | 5.84 Billion USD | 18.4% |
| 2022 Q4 | 5.84 Billion USD | 6.0% |
| 2022 Q1 | 5.05 Billion USD | 2.45% |
| 2021 Q1 | 3.66 Billion USD | 2.82% |
| 2021 Q4 | 4.93 Billion USD | 17.49% |
| 2021 FY | 4.93 Billion USD | 38.54% |
| 2021 Q3 | 4.19 Billion USD | 7.53% |
| 2021 Q2 | 3.9 Billion USD | 6.64% |
| 2020 FY | 3.56 Billion USD | 3.92% |
| 2020 Q4 | 3.56 Billion USD | 7.66% |
| 2020 Q1 | 2.75 Billion USD | -19.68% |
| 2020 Q3 | 3.3 Billion USD | 2.96% |
| 2020 Q2 | 3.21 Billion USD | 16.71% |
| 2019 FY | 3.42 Billion USD | 29.52% |
| 2019 Q1 | 2.75 Billion USD | 4.1% |
| 2019 Q2 | 2.94 Billion USD | 7.02% |
| 2019 Q3 | 3.21 Billion USD | 9.06% |
| 2019 Q4 | 3.42 Billion USD | 6.59% |
| 2018 Q1 | 2.3 Billion USD | 0.15% |
| 2018 Q3 | 2.51 Billion USD | 5.12% |
| 2018 Q4 | 2.64 Billion USD | 4.99% |
| 2018 FY | 2.64 Billion USD | 14.9% |
| 2018 Q2 | 2.39 Billion USD | 3.95% |
| 2017 Q2 | 1.63 Billion USD | 2.0% |
| 2017 Q3 | 2.37 Billion USD | 44.82% |
| 2017 Q4 | 2.3 Billion USD | -3.02% |
| 2017 Q1 | 1.6 Billion USD | -1.91% |
| 2017 FY | 2.3 Billion USD | 40.52% |
| 2016 Q2 | 1.41 Billion USD | 28.45% |
| 2016 Q3 | 1.54 Billion USD | 8.9% |
| 2016 Q4 | 1.63 Billion USD | 6.11% |
| 2016 FY | 1.63 Billion USD | 62.65% |
| 2016 Q1 | 1.1 Billion USD | 9.58% |
| 2015 Q1 | 862.62 Million USD | 3.92% |
| 2015 FY | 1 Billion USD | 21.37% |
| 2015 Q4 | 1 Billion USD | 8.1% |
| 2015 Q2 | 930.33 Million USD | 7.85% |
| 2015 Q3 | 931.93 Million USD | 0.17% |
| 2014 Q4 | 830.06 Million USD | 5.71% |
| 2014 Q1 | 666.82 Million USD | 5.92% |
| 2014 FY | 830.06 Million USD | 31.85% |
| 2014 Q3 | 785.26 Million USD | 15.63% |
| 2014 Q2 | 679.1 Million USD | 1.84% |
| 2013 Q4 | 629.56 Million USD | 76.15% |
| 2013 FY | 629.56 Million USD | 90.54% |
| 2013 Q2 | 334.21 Million USD | 1.19% |
| 2013 Q1 | 330.28 Million USD | -0.04% |
| 2013 Q3 | 357.4 Million USD | 6.94% |
| 2012 Q3 | 296.53 Million USD | -4.95% |
| 2012 FY | 330.41 Million USD | 0.44% |
| 2012 Q2 | 311.97 Million USD | 6.26% |
| 2012 Q1 | 293.59 Million USD | -10.75% |
| 2012 Q4 | 330.41 Million USD | 11.43% |
| 2011 Q2 | 416.66 Million USD | -9.34% |
| 2011 Q3 | 371.22 Million USD | -10.91% |
| 2011 Q4 | 328.96 Million USD | -11.38% |
| 2011 FY | 328.96 Million USD | -32.81% |
| 2011 Q1 | 459.6 Million USD | -6.12% |
| 2010 Q3 | 464.64 Million USD | -5.88% |
| 2010 Q1 | 502.66 Million USD | -29.44% |
| 2010 Q2 | 493.68 Million USD | -1.79% |
| 2010 FY | 489.58 Million USD | -31.28% |
| 2010 Q4 | 489.58 Million USD | 5.37% |
| 2009 Q4 | 712.39 Million USD | 50.67% |
| 2009 FY | 712.39 Million USD | 206.55% |
| 2009 Q1 | 189.63 Million USD | -18.4% |
| 2009 Q2 | 159.01 Million USD | -16.15% |
| 2009 Q3 | 472.81 Million USD | 197.34% |
| 2008 Q3 | 264.71 Million USD | 29.3% |
| 2008 Q4 | 232.38 Million USD | -12.21% |
| 2008 Q2 | 204.73 Million USD | -13.62% |
| 2008 Q1 | 237.01 Million USD | -14.03% |
| 2008 FY | 232.38 Million USD | -15.71% |
| 2007 Q4 | 275.69 Million USD | -2.47% |
| 2007 Q2 | 308.79 Million USD | -4.97% |
| 2007 FY | 275.69 Million USD | -22.03% |
| 2007 Q3 | 282.68 Million USD | -8.46% |
| 2007 Q1 | 324.93 Million USD | -8.11% |
| 2006 FY | 353.6 Million USD | -5.48% |
| 2006 Q3 | 464.88 Million USD | 23.93% |
| 2006 Q1 | 398.75 Million USD | 6.59% |
| 2006 Q4 | 353.6 Million USD | -23.94% |
| 2006 Q2 | 375.11 Million USD | -5.93% |
| 2005 FY | 374.1 Million USD | -27.63% |
| 2005 Q2 | 436.64 Million USD | -10.42% |
| 2005 Q1 | 487.45 Million USD | -5.7% |
| 2005 Q3 | 398.1 Million USD | -8.83% |
| 2005 Q4 | 374.1 Million USD | -6.03% |
| 2004 Q2 | 538.11 Million USD | -7.61% |
| 2004 Q1 | 582.46 Million USD | 53.46% |
| 2004 FY | 516.91 Million USD | 36.19% |
| 2004 Q4 | 516.91 Million USD | 9.86% |
| 2004 Q3 | 470.5 Million USD | -12.56% |
| 2003 Q4 | 379.54 Million USD | -8.64% |
| 2003 Q3 | 415.43 Million USD | -11.7% |
| 2003 FY | 379.54 Million USD | -31.26% |
| 2003 Q1 | 496.87 Million USD | -10.01% |
| 2003 Q2 | 470.47 Million USD | -5.31% |
| 2002 Q1 | 666.84 Million USD | -5.49% |
| 2002 Q4 | 552.13 Million USD | -8.44% |
| 2002 FY | 552.13 Million USD | -21.74% |
| 2002 Q3 | 603.05 Million USD | -6.61% |
| 2002 Q2 | 645.73 Million USD | -3.17% |
| 2001 Q2 | 852.06 Million USD | 0.01% |
| 2001 Q4 | 705.55 Million USD | -14.54% |
| 2001 FY | 705.55 Million USD | -20.44% |
| 2001 Q3 | 825.64 Million USD | -3.1% |
| 2001 Q1 | 851.94 Million USD | -3.93% |
| 2000 FY | 886.82 Million USD | 299.65% |
| 2000 Q2 | 876.63 Million USD | 0.11% |
| 2000 Q4 | 886.82 Million USD | 2.41% |
| 2000 Q3 | 865.92 Million USD | -1.22% |
| 2000 Q1 | 875.69 Million USD | 294.63% |
| 1999 FY | 221.9 Million USD | -3.65% |
| 1999 Q1 | 250.8 Million USD | 8.9% |
| 1999 Q2 | 224.2 Million USD | -10.61% |
| 1999 Q3 | 209.7 Million USD | -6.47% |
| 1999 Q4 | 221.9 Million USD | 5.82% |
| 1998 Q3 | 233 Million USD | 6.3% |
| 1998 Q4 | 230.3 Million USD | -1.16% |
| 1998 Q2 | 219.2 Million USD | 0.05% |
| 1998 Q1 | 219.1 Million USD | 13.46% |
| 1998 FY | 230.3 Million USD | 19.26% |
| 1997 Q2 | 76.6 Million USD | -3.77% |
| 1997 FY | 193.1 Million USD | 188.64% |
| 1997 Q4 | 193.1 Million USD | 6.63% |
| 1997 Q1 | 79.6 Million USD | 18.98% |
| 1997 Q3 | 181.1 Million USD | 136.42% |
| 1996 FY | 66.9 Million USD | 15.74% |
| 1996 Q1 | 62.1 Million USD | 7.44% |
| 1996 Q2 | 66 Million USD | 6.28% |
| 1996 Q3 | 74.4 Million USD | 12.73% |
| 1996 Q4 | 66.9 Million USD | -10.08% |
| 1995 Q2 | 23 Million USD | -13.86% |
| 1995 FY | 57.8 Million USD | 101.39% |
| 1995 Q3 | 20 Million USD | -13.04% |
| 1995 Q4 | 57.8 Million USD | 189.0% |
| 1995 Q1 | 26.7 Million USD | -6.97% |
| 1994 FY | 28.7 Million USD | 63.07% |
| 1994 Q1 | 15.3 Million USD | -13.07% |
| 1994 Q2 | 13.3 Million USD | -13.07% |
| 1994 Q3 | 19.1 Million USD | 43.61% |
| 1994 Q4 | 28.7 Million USD | 50.26% |
| 1993 Q4 | 17.6 Million USD | 417.65% |
| 1993 Q3 | 3.4 Million USD | 0.0% |
| 1993 FY | 17.6 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | -355.758% |
| Alkermes plc | 2.13 Billion USD | -217.481% |
| Agenus Inc. | 313.91 Million USD | -2060.505% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -77.084% |
| Aptorum Group Limited | 20.64 Million USD | -32758.901% |
| Ardelyx, Inc. | 297.57 Million USD | -2179.095% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -785.911% |
| Bicycle Therapeutics plc | 595.34 Million USD | -1039.191% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -9102.066% |
| ChromaDex Corporation | 54.96 Million USD | -12239.18% |
| Chimerix, Inc. | 212.77 Million USD | -3087.47% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -23888.443% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -1438.004% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -204.189% |
| Precision BioSciences, Inc. | 159.78 Million USD | -4144.627% |
| Dyadic International, Inc. | 8.21 Million USD | -82415.054% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -21267.697% |
| Fortress Biotech, Inc. | 167.52 Million USD | -3948.391% |
| Lantern Pharma Inc. | 43.64 Million USD | -15438.322% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -4103.69% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -46651.72% |
| IO Biotech, Inc. | 150.71 Million USD | -4399.865% |
| Jaguar Health, Inc. | 50.76 Million USD | -13260.335% |
| Novavax, Inc. | 1.85 Billion USD | -265.545% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -1682.855% |
| Opthea Limited | 188.79 Million USD | -3492.385% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -714.116% |
| ContextLogic Inc. | 423 Million USD | -1503.335% |
| MiMedx Group, Inc. | 239.04 Million USD | -2737.144% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -3803.91% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -131089.541% |
| NextCure, Inc. | 129.41 Million USD | -5140.467% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -12471.563% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -18365.265% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -20896.585% |
| Vaxcyte, Inc. | 1.4 Billion USD | -381.712% |
| PDS Biotechnology Corporation | 59.39 Million USD | -11319.596% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -958.799% |
| Pharming Group N.V. | 462.85 Million USD | -1365.28% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -17433.886% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -979.0% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -35739.27% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -35739.27% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -4002.412% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -14875.836% |
| Acelyrin, Inc. | 742.69 Million USD | -813.181% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -102869.457% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -105820.772% |
| Summit Therapeutics Inc. | 202.94 Million USD | -3241.779% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -9018.922% |
| Senti Biosciences, Inc. | 119.48 Million USD | -5576.163% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -2870.153% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -3932.792% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -81978.023% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -141970.31% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -1345.486% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -5384.79% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -2366.678% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -1334.334% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -67016.348% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -3061.733% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -598941.919% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -1538.816% |
| Immix Biopharma, Inc. | 19.92 Million USD | -33937.905% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -1732.878% |
| MEI Pharma, Inc. | 41.37 Million USD | -16291.799% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -20828.553% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -1890.067% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -5685.547% |
| Fortress Biotech, Inc. | 167.52 Million USD | -3948.391% |
| Precigen, Inc. | 151.04 Million USD | -4390.183% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -19836.819% |
| AlloVir, Inc. | 190.79 Million USD | -3454.638% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -1701.591% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -1239.763% |
| ImmuCell Corporation | 43.8 Million USD | -15381.399% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -944.5% |
| Onconetix, Inc. | 88.82 Million USD | -7535.664% |
| PureTech Health plc | 693.97 Million USD | -877.287% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -6842.834% |
| Elevation Oncology, Inc. | 89.09 Million USD | -7512.561% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -109253.547% |
| Seer, Inc. | 436.26 Million USD | -1454.57% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -8211.711% |
| Innoviva, Inc. | 1.24 Billion USD | -445.402% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -5021.548% |
| ESSA Pharma Inc. | 149.12 Million USD | -4448.022% |
| GlycoMimetics, Inc. | 45.31 Million USD | -14866.096% |
| GT Biopharma, Inc. | 14.1 Million USD | -47969.367% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -2102.748% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -2705.967% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -1337.17% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -13277.728% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -7023.164% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -1073718.217% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -1097.531% |
| Aptose Biosciences Inc. | 12.92 Million USD | -52382.754% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -30568.445% |
| Soligenix, Inc. | 9.79 Million USD | -69124.062% |
| Century Therapeutics, Inc. | 360.69 Million USD | -1780.309% |
| Kura Oncology, Inc. | 448.93 Million USD | -1410.71% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -2392.057% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -39114.264% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -6014.891% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -3205.91% |
| Autolus Therapeutics plc | 375.38 Million USD | -1706.726% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -2595.205% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -1809.463% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -13703.849% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -925.829% |
| GRI Bio, Inc. | 2.95 Million USD | -229335.284% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -63850.613% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -3877.425% |
| IGM Biosciences, Inc. | 423.41 Million USD | -1501.779% |
| INmune Bio, Inc. | 57 Million USD | -11798.225% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -2948.056% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -7979.588% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -25868.311% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -98431.38% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -8915.642% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -4505.595% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -3997.851% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -977.202% |
| Verastem, Inc. | 149.71 Million USD | -4429.921% |
| Abeona Therapeutics Inc. | 64 Million USD | -10496.711% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -1224.232% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -4290.935% |
| Histogen Inc. | 19.07 Million USD | -35458.68% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -29842.847% |
| Surrozen, Inc. | 46.08 Million USD | -14618.114% |
| Organovo Holdings, Inc. | 6.34 Million USD | -106721.657% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -157307.871% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -4608.921% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -57365.743% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -8910.611% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -79509.203% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -1768.509% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -37381.807% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -1479.431% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -53676.226% |
| Apollomics, Inc. | 55.38 Million USD | -12144.944% |
| Amarin Corporation plc | 831.68 Million USD | -715.467% |
| Mesoblast Limited | 669.15 Million USD | -913.536% |
| Turnstone Biologics Corp. | 112.81 Million USD | -5911.707% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -1077.942% |
| Synaptogenix, Inc. | 31.11 Million USD | -21697.839% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -55564.043% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -1137.471% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -115393.964% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -92234.38% |
| Exelixis, Inc. | 2.94 Billion USD | -130.499% |
| Better Therapeutics, Inc. | 22.94 Million USD | -29460.681% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -1760.461% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -759.877% |
| NLS Pharmaceutics AG | 1.84 Million USD | -367167.217% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -84903.36% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -46052.48% |
| Gritstone bio, Inc. | 177.76 Million USD | -3715.124% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -7010.618% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -37868.898% |
| Avid Bioservices, Inc. | 336.55 Million USD | -1915.144% |
| Insmed Incorporated | 1.32 Billion USD | -409.995% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -70338.97% |
| MediWound Ltd. | 66.45 Million USD | -10104.949% |
| OmniAb, Inc. | 401.98 Million USD | -1587.154% |
| Alector, Inc. | 621.82 Million USD | -990.674% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -1791.274% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -126008.349% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -11863.076% |
| Zai Lab Limited | 1.03 Billion USD | -554.457% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -1317.505% |
| Aura Biosciences, Inc. | 255.07 Million USD | -2558.868% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -804.246% |
| Immunic, Inc. | 54.29 Million USD | -12390.298% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -2447.519% |
| Veracyte, Inc. | 1.13 Billion USD | -496.061% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -57264.73% |
| FibroGen, Inc. | 423.52 Million USD | -1501.332% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -192957.415% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -143084.982% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -124812.69% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 40.473% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -76925.633% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -1210.669% |
| TG Therapeutics, Inc. | 329.58 Million USD | -1957.759% |
| Galecto, Inc. | 38.22 Million USD | -17641.667% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -23550.813% |
| Fortrea Holdings Inc. | 4.35 Billion USD | -55.653% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -2781.05% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -27200.97% |
| XBiotech Inc. | 227.24 Million USD | -2884.517% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -7010.618% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -4656.036% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -2272.063% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -5203.949% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -1675.425% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -354.866% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -1758.916% |
| Vaxxinity, Inc. | 44.35 Million USD | -15191.202% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -1211.921% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -36344.658% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -2123.277% |
| NexImmune, Inc. | 8.59 Million USD | -78817.236% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -63194.323% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -39498.016% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 79.498% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -30517.43% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -1728860.524% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -3812.852% |
| Ainos, Inc. | 31.84 Million USD | -21199.381% |
| Pluri Inc. | 39.52 Million USD | -17058.163% |
| Prothena Corporation plc | 696.38 Million USD | -873.906% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -2299.76% |
| Celularity Inc. | 143.88 Million USD | -4613.43% |
| Rallybio Corporation | 115.62 Million USD | -5765.86% |
| Cue Biopharma, Inc. | 61.53 Million USD | -10922.439% |
| MeiraGTx Holdings plc | 458.16 Million USD | -1380.266% |
| Omeros Corporation | 378.26 Million USD | -1692.932% |
| Humacyte, Inc. | 128.22 Million USD | -5189.306% |
| Immunocore Holdings plc | 597 Million USD | -1036.029% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -21596.494% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -9796.552% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -546.377% |
| CalciMedica, Inc. | 12.18 Million USD | -55559.475% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -2573.805% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -3868.279% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -2080.496% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -1099.738% |
| Pulmatrix, Inc. | 33.95 Million USD | -19872.045% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -24883.817% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -4714.854% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -421.309% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -5109.431% |
| Cytokinetics, Incorporated | 824.31 Million USD | -722.756% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -32007.688% |
| Nutriband Inc. | 7.51 Million USD | -90121.738% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -8489.947% |
| Vor Biopharma Inc. | 209.82 Million USD | -3132.222% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 6.097% |
| Evogene Ltd. | 51.1 Million USD | -13171.965% |
| ProKidney Corp. | 420.55 Million USD | -1512.668% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -12268.659% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -71138.539% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -1141.28% |
| CorMedix Inc. | 82.05 Million USD | -8164.819% |
| BioLineRx Ltd. | 63.92 Million USD | -10509.475% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -1584.715% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -23950.025% |
| Atai Life Sciences N.V. | 293.47 Million USD | -2210.942% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -4057.5% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -5222.723% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -1106.723% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -6912.177% |
| MediciNova, Inc. | 66.26 Million USD | -10134.057% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -7611.497% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -151884.587% |
| GeoVax Labs, Inc. | 9.28 Million USD | -72957.708% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -1052.957% |
| Biomea Fusion, Inc. | 199.92 Million USD | -3292.292% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -256.356% |
| Mereo BioPharma Group plc | 66.49 Million USD | -10098.811% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -1298.096% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -1006.596% |
| Absci Corporation | 234.48 Million USD | -2792.403% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -92615.065% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -1895.377% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -4008.326% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -1188.585% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -2342.304% |
| Allakos Inc. | 243.61 Million USD | -2684.002% |
| Imunon, Inc. | 21.91 Million USD | -30842.995% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -2531.845% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -991.218% |
| BioAtla, Inc. | 119.65 Million USD | -5567.909% |
| NLS Pharmaceutics AG | 1.84 Million USD | -367167.217% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -210524.441% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -955.027% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -6969.481% |
| XOMA Corporation | 234.3 Million USD | -2794.613% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -2965.567% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -5289.297% |
| aTyr Pharma, Inc. | 122.06 Million USD | -5456.053% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -4306.741% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -1068.783% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -1282.907% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -6039.376% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -44644.058% |
| Akari Therapeutics, Plc | 4.35 Million USD | -155631.504% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -39707.328% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -291.29% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -219813.677% |
| UroGen Pharma Ltd. | 178.31 Million USD | -3703.527% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -1340.745% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -1220328.997% |
| Orgenesis Inc. | 14.55 Million USD | -46506.013% |
| Entera Bio Ltd. | 11.76 Million USD | -57546.468% |
| GH Research PLC | 226.3 Million USD | -2896.954% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -12300.093% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -6212.695% |
| Xencor, Inc. | 952.69 Million USD | -611.889% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -87031.379% |
| Replimune Group, Inc. | 487.72 Million USD | -1290.568% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -83929.64% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -945.911% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -219813.677% |
| Portage Biotech Inc. | 7.77 Million USD | -87084.818% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -151884.587% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -2348.9% |
| OncoCyte Corporation | 74.89 Million USD | -8955.85% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -333460.244% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -117102.789% |
| Purple Biotech Ltd. | 44.3 Million USD | -15208.805% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -19773.724% |
| scPharmaceuticals Inc. | 94.47 Million USD | -7078.428% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -37484.499% |
| HilleVax, Inc. | 344.43 Million USD | -1869.059% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -213442.412% |
| Tharimmune, Inc. | 10.94 Million USD | -61857.459% |
| Genprex, Inc. | 10.67 Million USD | -63458.863% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -1266.823% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -6946.199% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -279459.233% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -162718.463% |
| OKYO Pharma Limited | 1.54 Million USD | -439935.387% |
| Savara Inc. | 177.56 Million USD | -3719.528% |
| Curis, Inc. | 77.28 Million USD | -8675.791% |
| Daré Bioscience, Inc. | 21.28 Million USD | -31767.487% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -10505.526% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -83774.685% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -34911.651% |
| BeiGene, Ltd. | 5.8 Billion USD | -16.827% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -55632.657% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -224.722% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -1794.703% |
| Erasca, Inc. | 395.29 Million USD | -1615.699% |
| bluebird bio, Inc. | 619.16 Million USD | -995.371% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -156770.88% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 0.87% |
| DBV Technologies S.A. | 182.98 Million USD | -3606.353% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -156770.88% |
| Moderna, Inc. | 18.42 Billion USD | 63.193% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -37129.549% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -58437.088% |
| Molecular Templates, Inc. | 35.38 Million USD | -19067.699% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -4805.151% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -759.677% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -2132.756% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -6424.645% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -1356.554% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -2063.786% |
| MacroGenics, Inc. | 306.82 Million USD | -2110.451% |
| RenovoRx, Inc. | 1.46 Million USD | -462526.671% |
| Adicet Bio, Inc. | 207.29 Million USD | -3171.718% |
| Prime Medicine, Inc. | 193.85 Million USD | -3398.619% |
| Aditxt, Inc. | 44.57 Million USD | -15113.911% |
| Adagene Inc. | 115.72 Million USD | -5760.343% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -152163.566% |
| Quantum-Si incorporated | 298.25 Million USD | -2173.967% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -355.955% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -87875.078% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -1830.679% |
| SciSparc Ltd. | 11.18 Million USD | -60552.003% |
| Vericel Corporation | 353.65 Million USD | -1817.708% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -55433.646% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -11819.216% |
| Generation Bio Co. | 374.75 Million USD | -1709.73% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -2563.138% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -4177.124% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -1886.761% |
| Invivyd, Inc. | 229.18 Million USD | -2859.28% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -703.586% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -55631.278% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -3618.464% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -33106.556% |
| 2seventy bio, Inc. | 565.42 Million USD | -1099.469% |
| ADMA Biologics, Inc. | 329.18 Million USD | -1960.291% |
| Clene Inc. | 52.34 Million USD | -12857.542% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -11447.092% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -5121.263% |
| GeoVax Labs, Inc. | 9.28 Million USD | -72957.708% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -937.497% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -6445.731% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -5101.561% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -6852.296% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -9452.667% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -2696.134% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -246.01% |
| Evaxion Biotech A/S | 12.88 Million USD | -52520.898% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -2590.672% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -801.052% |
| Trevena, Inc. | 40.6 Million USD | -16602.64% |
| Surrozen, Inc. | 46.08 Million USD | -14618.114% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -2902.832% |
| Cingulate Inc. | 3.49 Million USD | -194149.787% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -40684.816% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -10224.413% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -57942.991% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -2425.764% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -805.541% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -5287.242% |
| Clearmind Medicine Inc. | 4.32 Million USD | -156733.879% |
| Kronos Bio, Inc. | 213.27 Million USD | -3079.923% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -4144.547% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -79124.576% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -1740.513% |
| Statera Biopharma, Inc. | 21.16 Million USD | -31936.882% |
| ImmunityBio, Inc. | 504.45 Million USD | -1244.45% |
| Korro Bio, Inc. | 221.66 Million USD | -2959.648% |
| Kineta, Inc. | 10.28 Million USD | -65867.386% |
| BioVie Inc. | 25.2 Million USD | -26804.214% |
| Codexis, Inc. | 136.56 Million USD | -4866.357% |
| Celularity Inc. | 143.88 Million USD | -4613.43% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -967.455% |
| Celcuity Inc. | 191.21 Million USD | -3446.767% |
| Virax Biolabs Group Limited | 5.48 Million USD | -123571.505% |
| Cibus, Inc. | 544.41 Million USD | -1145.77% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -5287.157% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -32912.592% |
| IN8bio, Inc. | 33.7 Million USD | -20019.573% |
| Kodiak Sciences Inc. | 479.37 Million USD | -1314.79% |
| Annexon, Inc. | 297.67 Million USD | -2178.367% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -3820.066% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -4833.554% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -32206.516% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -126.821% |
| Eyenovia, Inc. | 28.77 Million USD | -23465.86% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -2841.988% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -93782.987% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -11031.712% |
| Arcellx, Inc. | 825.13 Million USD | -721.942% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -8207.639% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -1367.115% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -21955.633% |
| Moolec Science SA | 24.05 Million USD | -28098.518% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -2086.895% |
| Geron Corporation | 394.07 Million USD | -1621.015% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -6568.083% |
| Royalty Pharma plc | 16.38 Billion USD | 58.6% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -1039.911% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -96859.062% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -56289.198% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -2900.136% |
| Humacyte, Inc. | 128.22 Million USD | -5189.306% |
| Structure Therapeutics Inc. | 482.01 Million USD | -1307.026% |
| 89bio, Inc. | 596.26 Million USD | -1037.424% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -2589.69% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -366500.378% |
| Genelux Corporation | 27.89 Million USD | -24214.728% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -7485.995% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -2856.081% |
| Notable Labs, Ltd. | 19.54 Million USD | -34607.062% |
| Liquidia Corporation | 120.43 Million USD | -5531.529% |
| Mustang Bio, Inc. | 17.74 Million USD | -38126.282% |
| Immunovant, Inc. | 666.71 Million USD | -917.247% |
| Quantum-Si incorporated | 298.25 Million USD | -2173.967% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -4596.717% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -12422.354% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -3763.436% |
| Acasti Pharma Inc. | 73.3 Million USD | -9152.533% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -148882.609% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -25868.311% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -602.956% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -130578.5% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -29670.892% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -13042.854% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -3653.428% |
| PepGen Inc. | 143.05 Million USD | -4641.008% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -17646.309% |
| United Therapeutics Corporation | 7.16 Billion USD | 5.37% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -35251.092% |
| Solid Biosciences Inc. | 164.93 Million USD | -4011.888% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -115393.964% |
| Immuneering Corporation | 102.58 Million USD | -6511.237% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -157307.871% |
| Silo Pharma, Inc. | 7.74 Million USD | -87454.655% |
| Belite Bio, Inc | 94.64 Million USD | -7066.065% |
| XOMA Corporation | 234.3 Million USD | -2794.613% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -2808.429% |
| Bionomics Limited | 27.64 Million USD | -24429.221% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -1589.596% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -6215.517% |
| uniQure N.V. | 831.68 Million USD | -715.462% |
| Cassava Sciences, Inc. | 151.66 Million USD | -4371.827% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -152163.566% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -2376.261% |
| Forte Biosciences, Inc. | 38.98 Million USD | -17298.94% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -166409.138% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -18314.127% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -93782.987% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -192957.415% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -57273.378% |
| Altimmune, Inc. | 210.64 Million USD | -3119.762% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -771.871% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -6215.517% |
| Compugen Ltd. | 121.33 Million USD | -5489.618% |
| Peak Bio, Inc. | 2.59 Million USD | -261110.438% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -3835.603% |
| Benitec Biopharma Inc. | 52.21 Million USD | -12890.054% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -1883.89% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -19403.946% |
| Zura Bio Limited | 100.84 Million USD | -6625.412% |
| PolyPid Ltd. | 15.37 Million USD | -44019.874% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -5585.585% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -19403.946% |
| Instil Bio, Inc. | 325.63 Million USD | -1982.765% |
| argenx SE | 4.54 Billion USD | -49.305% |
| Immunome, Inc. | 148.54 Million USD | -4465.846% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -4223.255% |
| Verona Pharma plc | 308.12 Million USD | -2101.097% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -7699.201% |
| Shattuck Labs, Inc. | 159.56 Million USD | -4150.399% |
| CervoMed Inc. | 9.97 Million USD | -67907.949% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -3498.775% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -59454.856% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -3680.333% |
| Moolec Science SA | 24.05 Million USD | -28098.518% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -110764.392% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -3821.553% |
| AnaptysBio, Inc. | 452.38 Million USD | -1399.176% |
| Design Therapeutics, Inc. | 289.64 Million USD | -2241.54% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -9212.883% |
| NeurAxis, Inc. | 509.49 Thousand USD | -1331035.157% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -125077.316% |
| Lumos Pharma, Inc. | 40.63 Million USD | -16589.077% |
| Achilles Therapeutics plc | 161.45 Million USD | -4100.591% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -7699.201% |
| 180 Life Sciences Corp. | 5.25 Million USD | -128850.241% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -9529.872% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -79124.576% |
| Nutriband Inc. | 7.51 Million USD | -90121.738% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -2562.929% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -3302.947% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -8799.001% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -11610.248% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -1188.051% |
| Palisade Bio, Inc. | 14.05 Million USD | -48164.354% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -3125.044% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -364.619% |
| Neurogene Inc. | 222.57 Million USD | -2947.138% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -948.854% |
| AEON Biopharma, Inc. | 6.84 Million USD | -98981.183% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -1397.035% |
| Sesen Bio, Inc. | 189.17 Million USD | -3485.116% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -2394.641% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -49361.576% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -769.11% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -2440.172% |
| Athira Pharma, Inc. | 160.24 Million USD | -4132.336% |
| Vaccinex, Inc. | 3.63 Million USD | -186683.448% |
| HCW Biologics Inc. | 28.51 Million USD | -23685.466% |
| XOMA Corporation | 234.3 Million USD | -2794.613% |
| Nektar Therapeutics | 398.03 Million USD | -1603.906% |
| Arvinas, Inc. | 1.3 Billion USD | -419.861% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -39707.328% |
| Merus N.V. | 458.49 Million USD | -1379.214% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -3218.608% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -3663.572% |
| Rezolute, Inc. | 132.73 Million USD | -5009.432% |
| Clene Inc. | 52.34 Million USD | -12857.542% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -45344.669% |
| BeyondSpring Inc. | 24.8 Million USD | -27238.387% |
| Synlogic, Inc. | 75.55 Million USD | -8876.978% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -57075.072% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -72327.456% |
| Peak Bio, Inc. | 2.59 Million USD | -261110.438% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -3779.192% |
| Krystal Biotech, Inc. | 818.35 Million USD | -728.749% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -2720.73% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -834.447% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -189493.992% |
| MannKind Corporation | 475.19 Million USD | -1327.217% |
| Ikena Oncology, Inc. | 192.09 Million USD | -3430.656% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -50611.134% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -5719.603% |
| Gossamer Bio, Inc. | 311.91 Million USD | -2074.338% |
| CohBar, Inc. | 16.36 Million USD | -41341.067% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -19187.623% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -92615.065% |
| Legend Biotech Corporation | 1.84 Billion USD | -266.876% |
| Mural Oncology plc | 301.74 Million USD | -2147.629% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -21627.077% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -119294.779% |
| Disc Medicine, Inc. | 367.99 Million USD | -1742.984% |
| Champions Oncology, Inc. | 26.13 Million USD | -25853.264% |
| REGENXBIO Inc. | 573.97 Million USD | -1081.613% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -250339.222% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -4292.955% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -56063.82% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -1894.532% |
| Vaxart, Inc. | 91.83 Million USD | -7285.503% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -11221.648% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -4472.405% |
| Cellectis S.A. | 334.27 Million USD | -1928.931% |
| Longeveron Inc. | 12.17 Million USD | -55591.468% |
| Repare Therapeutics Inc. | 253.9 Million USD | -2571.162% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -107.748% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -3276.753% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -224.722% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -417260.431% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -2342.146% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -4058.302% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -4788.216% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -26473.572% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 70.163% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -487.747% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -55433.646% |
| Veru Inc. | 50.59 Million USD | -13304.453% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -14788.387% |
| Cingulate Inc. | 3.49 Million USD | -194149.787% |
| Passage Bio, Inc. | 150.54 Million USD | -4405.036% |
| Context Therapeutics Inc. | 16.06 Million USD | -42122.617% |
| Exicure, Inc. | 11.58 Million USD | -58467.418% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -1703.522% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -4095.758% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -38717.004% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -1938.23% |
| Nuvalent, Inc. | 732.38 Million USD | -826.032% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -45283.238% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -7473.204% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -47691.607% |
| OmniAb, Inc. | 401.98 Million USD | -1587.154% |
| Anew Medical, Inc. | 19.45 Million USD | -34758.776% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -25275.912% |
| Lipocine Inc. | 23 Million USD | -29386.047% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -4751.05% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -2119.53% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -7979.588% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -5480.144% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -85370.788% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -668.705% |
| Ocugen, Inc. | 64.54 Million USD | -10407.238% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -5345.682% |
| Q32 Bio Inc. | 306.11 Million USD | -2115.513% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -161071.744% |
| Alumis Inc. Common Stock | 89.61 Million USD | -7468.302% |
| Equillium, Inc. | 50.53 Million USD | -13321.941% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -8919.359% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -16332.101% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -398647.393% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -25844.329% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -10424.522% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -181866.766% |
| Dominari Holdings Inc. | 57.55 Million USD | -11683.083% |
| Edesa Biotech, Inc. | 8.89 Million USD | -76185.418% |
| vTv Therapeutics Inc. | 11.01 Million USD | -61454.792% |
| Bio-Techne Corporation | 2.81 Billion USD | -141.082% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -623.72% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -735.803% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -2342.55% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -16163.266% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -915.912% |
| Nkarta, Inc. | 378.88 Million USD | -1690.017% |
| BioCardia, Inc. | 2.98 Million USD | -226954.135% |
| Iterum Therapeutics plc | 26.25 Million USD | -25727.743% |